Business
Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication
Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following
About this update from Lucid Diagnostics Inc.
[{"type":"text","content":"Study demonstrates outstanding clinical utility including an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy following EsoGuard esophageal precancer testing \nNEW YORK, Dec. 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (\"Lucid\" or the \"Company\"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its CLinical Utility of EsoGuard (CLUE) study has been accepted for publication in the peer-reviewed journal Medicina. This is the fourth peer-reviewed publication presenting outstanding clinical utility data for the EsoGuard® Esophageal DNA Test. In addition to demonstrating near-perfect provider decision impact, consistent with previous EsoGuard clinical utility studies, the study documented an exceptionally high 85% patient compliance with referral to confirmatory upper endoscopy (EGD) following EsoGuard esophageal precancer testing in a real-world clinical setting.\n\n \n \n \n \n \n \n\n \n\"The final results from the CLUE study strongly support the clinical utility of EsoGuard as an effective triage tool for esophageal precancer testing of at-risk patients and we are deeply grateful to our investigators across eight clinical centers for their commitment to esophageal cancer prevention,\" said Victoria T. Lee, M.D., Lucid's Chief Medical Officer. \"EsoGuard enables physicians to effectively triage patients at increased risk for esophageal precancer to confirmatory upper endoscopy. Once again, physicians consistently utilized our non-invasive EsoGuard test to appropriately refer patients to endoscopy, allowing the vast majority of patients to avoid this more expensive and invasive procedure. Patients, in turn, showed an exceptionally high level of compliance with their physician's referral to EGD. This patient compliance data and the study's full provider impact data supplements our strong evidence base of clinical validity, clinical utility and analytical validity data supporting our ongoing discussions with payors and other key stakeholders.\"\nThe full manuscript, entitled Real-world Clinical Utility of a Methylated DNA Biomarker Assay on Samples Collected with a Swallowable Capsule-balloon for Detection of Barrett's Esophagus (BE) is expected to be available in an upco...